Posted by laima on February 4, 2007, at 10:50:08
In reply to Re: Why don't they make a transdermal Nardil?, posted by halcyondaze on February 2, 2007, at 14:43:45
We can entertain the idea that poor sales could stem from the fact selegeline never was known to be a super powerful antidepressent in the first place. Let me toss out a speculation- now that they've spent how many billions of dollars to develope the patch technology- why would they want to throw it all away? I bet there must be some minds at work now, trying to figure out what they can do with some of the technology they developed using selelgeline- like trying to decide which other maoi might ne the next most promising to tackle. They could conceivanly build on some of what they've already learned, perhaps then the next one won't be so expensive to develope. Kind of like consumer electronics...
> It is very hard to make a drug that can adequately cross the blood brain barrier without being absorbed through the gut. When there is financial incentive, there is reason to make alternate formulations (i.e. transdermal methylphenidate, orally disintigrating olanzapine, intramuscular risperidone) but it seems like the market is just not there for MAOIs. Especially given the poor sales of EMSAM.
poster:laima
thread:728900
URL: http://www.dr-bob.org/babble/20070201/msgs/729603.html